On April 29, 2026, Valneva SE announced a private placement to issue 15,893,817 new shares for €37 million, with potential additional shares worth €47 million if warrants are exercised. The transaction is expected to close on May 5, 2026, and will aid in advancing their vaccine pipeline and general corporate purposes.